| Jun 3 |
Arrowhead says phase 3 trial of rare metabolic disease asset plozasiran meets goals
|
| Jun 3 |
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
|
| May 31 |
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
|
| May 29 |
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
|
| May 28 |
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
|
| May 27 |
Arrowhead Pharmaceuticals: Hoping Something Sticks
|
